REgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lomber SPINE unresponsive to conventional therapy

Project Information

RESPINE

Grant agreement ID: 732163

DOI

10.3030/732163

Project closed

EC signature date 9 December 2016

Start date 1 January 2017

End date 30 June 2023

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 5 555 836,25

EU contribution

€ 5 555 836,25

Coordinated by

CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (9)

RESPINE final clinical trial report
Report describing the role of miRNAs in regulating the immunosuppressive capacity of human MSCs
Midterm recruitment report
Dissemination and Communication

CHUM will be prepared logo, poster, video, brochure and website

Report describing the profile of inflammatory markers and cytokine meditators that contribute to the inflammatory nature of the degenerated disc
Registration of clinical trial on EudraCT and Clinicaltrials.gov

Registration of clinical trial on EudraCT and Clinicaltrials.gov. Transfer the register number to the european comission

Report describing the identification of inflammatory mediators capable of “licensing”: MSCs in vitro
Minutes of the Meeting with complementary projects

A Meeting with representatives from these and any other complementary projects will be set-up in M24 to discuss and exchange best-practices regarding scientific, standardisation, economic and regulatory issues related to projects’ results. Networking and exchange of best practices with similar initiatives will also take place throughout the project at conferences and other events.

"Report describing the functional effects of ""licensed"" allogeneic MSCs on the activation of T cells and macrophages in vitro"

Report describing the functional effects of licensed allogeneic MSCs on the activation of T cells and macrophages in vitro

Websites, patent fillings, videos etc. (2)

RESPINE final workshop

RESPINE workshops will be organized the final workshop in M78 by CHUM The target audience will include scientists clinicians pathologists members of standards working groups patient groups future potential partners investors students and regulators

RESPINE midterm workshop

RESPINE workshops will be organized at M24 by UCBMThe target audience will include scientists clinicians pathologists members of standards working groups patient groups future potential partners investors students and regulators The RESPINE clinical study its evaluation and impacts will be presented along with the database

Publications

Peer reviewed articles (6)

Mesenchymal Stem Cell-Derived Exosomes: The New Frontier for the Treatment of Intervertebral Disc Degeneration

Author(s): Veronica Tilotta, Gianluca Vadalà ,Luca Ambrosio, Fabrizio Russo, Claudia Cicione, Giuseppina Di Giacomo, Rocco Papalia andVincenzo Denaro
Published in: Applied Sciences, 2021, ISSN 2076-3417
Publisher: MDPI
DOI: 10.3390/app112311222

miR-155 Contributes to the Immunoregulatory Function of Human Mesenchymal Stem Cells

Author(s): Yves-Marie Pers, Claire Bony, Isabelle Duroux-Richard, Laurène Bernard, Marie Maumus, Said Assou, Frank Barry, Christian Jorgensen, Danièle Noël
Published in: Frontiers in Immunology, Issue 12, 2021, ISSN 1664-3224
Publisher: frontiersin
DOI: 10.3389/fimmu.2021.624024

Mesenchymal Stromal Cell-Derived Extracellular Vesicles Regulate the Mitochondrial Metabolism via Transfer of miRNAs

Author(s): Claire Loussouarn, Yves-Marie Pers, Claire Bony, Christian Jorgensen, Danièle Noël
Published in: Frontiers in Immunology, Issue 12, 2021, ISSN 1664-3224
Publisher: frontiersin
DOI: 10.3389/fimmu.2021.623973

Combinatorial conditioning of adipose derived‐mesenchymal stem cells enhances their neurovascular potential: Implications for intervertebral disc degeneration

Author(s): Abbie. L. A. Binch, Stephen M. Richardson, Judith A. Hoyland, Frank P. Barry
Published in: JOR SPINE, Issue 2/4, 2019, ISSN 2572-1143
Publisher: JOR SPINE
DOI: 10.1002/jsp2.1072

Allogenic bone marrow–derived mesenchymal stromal cell–based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study)

Author(s): Yves-Marie Pers, Robert Soler-Rich, Gianluca Vadalà, Rosanna Ferreira, Claire Duflos, Marie-Christine Picot, Fanchon Herman, Sylvie Broussous, Ana Sánchez, David Noriega, Francisco Ardura, Mercedes Alberca Zaballos, Verónica García, Virginia Gordillo Cano, Margarita González-Vallinas, Vicenzo Denaro, Fabrizio Russo, Jérôme Guicheux, Joan Vilanova, Lluís Orozco, Hans-Jörg Meisel, Matias Al
Published in: Annals of the Rheumatic Diseases, Issue 83, 2025, Page(s) 1572-1583, ISSN 0003-4967
Publisher: BMJ Publishing Group
DOI: 10.1136/ard-2024-225771

A Hyaluronan and Platelet-Rich Plasma Hydrogel for Mesenchymal Stem Cell Delivery in the Intervertebral Disc: An Organ Culture Study

Author(s): Fabrizio Russo, Luca Ambrosio, Marianna Peroglio, Wei Guo, Sebastian Wangler, Jan Gewiess, Sibylle Grad, Mauro Alini, Rocco Papalia, Gianluca Vadalà, Vincenzo Denaro
Published in: International Journal of Molecular Sciences, Issue 22/6, 2021, Page(s) 2963, ISSN 1422-0067
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms22062963